# Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial

> **NCT07293260** · PHASE3 · RECRUITING · sponsor: **Amgen** · enrollment: 406 (estimated)

## Conditions studied

- Cardiovascular Disease

## Interventions

- **DRUG:** Olpasiran
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07293260
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-23
- **Primary completion:** 2028-06-15
- **Final completion:** 2028-06-15
- **Target enrollment:** 406 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07293260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07293260, "Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07293260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*